ACROBiosystems社 Combination of CTLA-4 and PD-1 blockers for the treatment of cancer
Combination of CTLA-4 and PD-1 blockers for the treatment of cancer
Immune checkpoint regulators, such as programmed cell death protein 1 (PD-1) and Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on T cells, help to enhance the body's own immune anticancer response. Targeting checkpoints of immune cell activation has been demonstrated to be the most effective approach for the activation of anti-tumor immune responses. CTLA-4 and PD-1, both inhibitory checkpoints that are commonly seen on activated T-cells have been found to be the most reliable targets for the treatment of cancer.
However, the effect is not good when administered as monotherapy. Efficacy of the combination has been shown in several published studies and is under evaluation in multiple ongoing studies. A combination of CTLA-4 and PD-1 blockers was suggested to have a synergistic effect on activation of anti-tumor immune response and to increase the response rates in patients.
Protocols are available for free！
High bioactivity verified by ELISA
Quantitative Analysis of CTLA-4 x OX40 Bispecific Antibody in Human Serum by Intact Assay. Immobilized Human OX40 Protein, His Tag (MALS verified) (Cat. No. OX0-H5224) at 2 μg/mL, add increasing concentrations of CTLA-4 x OX40 bispecific antibody in 50% Human serum and then add Biotinylated Human CTLA-4, His, Avitag (Cat. No. CT4-H82E3) at 0.2 μg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 4 ng/mL (Intact assay, routinely tested).
High bioactivity verified by SPR
Biotinylated Human CTLA-4, His, Avitag (Cat. No. CT4-H82E3) captured on Biotin CAP - Series S sensor Chip can bind Yervoy (Ipilimumab) with an affinity constant of 0.635 nM as determined in an SPR assay (Biacore T200) (Routinely tested).
Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。